Clinical Trials
Below are current clinical trials.
272 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of the study is to determine the extent of donor site morbidity after harvesting the medial femoral condyle for scaphoid nonunion treatment. The outcomes being measured are: superficial infection, deep infection, pain (short term), pain (long term), knee function and quality of scar.
-
Scottsdale/Phoenix, Ariz.
The purpose of this open-label extension of CDI-001 (subsequently referred to as PRISM 3) is to evaluate the safety and efficacy in reducing recurrence of CDI in adults who had a recurrence within 8 weeks of receiving CP101 or placebo in PRISM 3. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in the extension study and administered CP101. Approximately 70 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.
-
Rochester, Minn.
The purpose of this study is to compare cardiopulmonary exercise testing with no filter to pre- and post-flow sensor placement.
-
Rochester, Minn.
The purpose of this study is to provide the lab with a source of human PBMCs and serum from normal and HIV-1-infected individuals. We wish to analyze cells from HIV-infected and non-HIV infected individuals for levels of various proteins and mRNAs that are relevant to HIV research.
-
Rochester, Minn.
The purpose of this study is to determine if a medical record prompt at the time of a medical consult will help to address lapses in routine immunizations, including the HPV vaccine.
-
Rochester, Minn.
The purpose of this study is to evaluate the safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to assess the effectiveness and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.
-
Rochester, Minn.
This research trial will study the immune respone to COVID-19 vaccination in patients with rheumatic diseases.
-
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care (SOC) can alleviate the immune-mediated cytokine release syndrome (CRS) and prevent progression to respiratory failure and/or death in high risk patients with COVID-19 pneumonia.
-
Rochester, Minn.
The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients who ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease.